Item 2.01. Completion of acquisition or disposition of Assets
On April 12, 2021 a new Nevada corporation was formed to merge and survive the
bankrupt Immune Pharmaceuticals Inc (NJ).
The new corporation retains the same name however is registered in the state of
Nevada. The company further has updated its address.
The new corporation is not subject to chapter 7 bankruptcy and has no
association with any legal issues relating to the previous corporation.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
On April 13, 2021, Devin J Shaw, age 34, has been appointed as the Chief Finance
Mr. Shaw is an investment banker, predominantly specializing in Collateral
trading, Equity & Debt capital market transactions.
In connection with his appointment to the board of Immune Pharmaceuticals as
CFO, Mr Shaw's role Will entail planning and implementing all financial
activities for the company.
The appointment as such carries no compensation and does not cover any expenses.
This is subject to change once full employment has been agreed with the company.
Item 8.01. Other Events
The company is working on documents to bring up to date all SEC filings.
The company is also working on full employment contracts for the interim CEO to
make this a permanent position and is further agreeing a contract with the new
CFO. The market will be updated of this in the coming weeks.
The new Nevada corporation is a new entity unrelated to any events surrounding
the previous bankruptcy.
The board will be announcing a new pharmaceutical asset once details have been
We will be applying to Finra once all SEC filings are up to date to have the "Q"
status removed, we expect this corporate action to be initiated within 30 days.
Exhibit Number Description
Exhibit 1 Certificate of charter
Exhibit 2 Business license
© Edgar Online, source Glimpses